ZM-02 / Zhongmou Therap - LARVOL DELTA

Safety and Efficacy of ZM-02 Optogenetic Gene Therapy Clinical Study for Advanced Retinitis Pigmentosa (ASGCT 2025) - P1 | "This trial indicated that ZM-02 has a notable safety and tolerability profile with no drug-related AEs. Efficacy results showed significant BCVA improvement, supported by MLTs, with an unexpected bonus in color perception. These findings suggest that ZM-02 holds promise in advanced RP treatment."

Clinical • Gene therapy • Metastases • CNS Disorders • Gene Therapies • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Safety and Efficacy of ZM-02 Optogenetic Gene Therapy Clinical Study for Advanced Retinitis Pigmentosa (ARVO 2025) - P1 | "Surprisingly, many treated patients also reported improvements in color vision. These results suggest that ZM-02 could be a new way to help people with advanced RP regain some of their vision and improve their quality of life."

Clinical • Gene therapy • Metastases • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Zhongmou Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Gene therapy • Gene Therapies • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Zhongmou Therapeutics

Gene therapy • New P1 trial • Gene Therapies • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa